Vertex Pharmaceuticals makes medicines for serious diseases that patients must take continuously, often for life. Most of its money comes from five approved drugs for cystic fibrosis, a genetic lung disease. The biggest of these is TRIKAFTA/KAFTRIO, which generated $10.3 billion in revenue in 2025 alone. Patients refill prescriptions regularly, which creates a steady, repeating stream of income. Alongside CF, Vertex now sells CASGEVY, a gene-editing therapy for sickle cell disease and a related blood disorder, and JOURNAVX, a first-of-its-kind non-opioid painkiller approved in January 2025. Together these products serve patients across more than 60 countries. The diagram below traces where the money goes.

Five years of financial data tell a clear story of growth. Revenue climbed from $7.6 billion in 2021 to $12.0 billion in 2025, a consistent upward line driven almost entirely by CF medicines. Gross margins have stayed remarkably stable across that entire period, sitting above 86% every year. That means for every dollar of product revenue, Vertex keeps more than 86 cents after manufacturing costs and royalties. That kind of consistency is unusual in any industry.

Free cash flow, which is the actual cash left over after the company pays its bills and invests in equipment, was positive and strong in four of the five years. In 2021 it was $2.4 billion. By 2022 it had grown to $3.9 billion. It dipped in 2024 to negative $0.8 billion, but that was not a sign of trouble. In 2024, Vertex spent approximately $5.0 billion to acquire Alpine Immune Sciences and its lead drug candidate, povetacicept. That one-time acquisition cost swamped the operating cash flows for the year. By 2025, free cash flow bounced back to $3.2 billion. The balance sheet reflects the same picture: Vertex holds $12.3 billion in cash and marketable securities as of December 31, 2025, with no meaningful debt.

The pipeline beyond CF is genuinely broad. Povetacicept is being tested for IgA nephropathy, primary membranous nephropathy, and generalized myasthenia gravis. Suzetrigine, the same molecule as JOURNAVX, is now in two Phase 3 trials for diabetic peripheral neuropathy. Zimislecel is a stem-cell therapy for type 1 diabetes, though dosing in its pivotal trial was temporarily paused in 2025 pending a manufacturing review. Inaxaplin targets a kidney disease that affects people of African ancestry, with interim data expected in late 2026 or early 2027. That is a lot of programs running at the same time, which means a lot of spending.

Research and development spending reached $3.9 billion in 2025, up from $3.6 billion in 2024 and $3.2 billion in 2023. Selling, general and administrative expenses jumped 20% in 2025 to $1.75 billion, largely to support the JOURNAVX launch. The company also wrote off $379 million in 2025 when VX-264, an encapsulated version of its diabetes therapy, failed its trial and was discontinued. These are real costs, and they remind readers that even a well-funded pipeline produces failures.

The risks are specific and documented. Revenue concentration is the most obvious: almost all of Vertex's income flows from CF medicines. If those drugs faced a serious competitor or a pricing collapse, the entire financial structure would feel it. Governments and insurers are already pushing back on drug prices, and the U.S. government has been considering new pricing rules. A second risk sits inside CASGEVY. The gene-editing therapy requires collecting cells from each individual patient, shipping them to a manufacturing facility, editing them, and sending them back. That process is complex, expensive, and hard to scale. In all of 2025, only 64 patients received a CASGEVY infusion, generating $115.8 million in revenue. A third risk is geographic: Vertex relies on suppliers in China and other countries for materials. Trade restrictions or supply chain disruptions could interrupt manufacturing. Finally, Vertex is betting heavily on drugs that have not yet been approved. If povetacicept, inaxaplin, zimislecel, or suzetrigine for nerve pain fail their late-stage trials, the billions spent on those programs produce nothing.

There is also a royalty dispute quietly running in the background. Royalty Pharma initiated arbitration in October 2025 arguing that the royalty rate on ALYFTREK, Vertex's newest CF medicine, should be around 8% rather than the 4% Vertex believes it owes. Vertex says it will fight this vigorously, but the outcome is unresolved. ALYFTREK generated $837.8 million in 2025 revenue, so the difference between a 4% and an 8% royalty rate is not trivial.

Vertex estimates that nearly 95% of people with CF could benefit from its five approved medicines, and that it is already treating nearly three quarters of CF patients in the U.S., Europe, Australia, and Canada. That is an impressive penetration rate, but it also signals that the CF market is maturing. Future CF growth will come from younger patients, new geographies, and the gradual transition to ALYFTREK rather than from a sudden surge in new patients. The engine is reliable, but it is not accelerating the way it once did.